Our Technologies


In Vivo and In Vitro Capabilities

Extensive in vitro and in vivo capabilities and expertise

CXR has extensive in-house in vivo capabilities and in vitro capabilities, supported by a full suite of modern laboratory equipment (including two Sciex 6500 triple-quad mass spectrometers, two further triple-quad mass spectrometers, a Xevo G2-XS QTOF/TOF plus a further TOF mass spectrometer, GC, GC-MS, HPLC, advanced microscopy and image analysis, a liquid scintillation counter, Quantitative PCR, full capability in Agilent gene analysis and Ingenuity bioinformatics).


Microarrays & Toxicogenomics

mRNA, miRNA, cGH, ChIP on chip, methylation…

CXR Biosciences employs its microarrays and toxicogenomics services to provide a detailed understanding of the cellular responses to compounds.

This is useful in a variety of research applications, but especially in Investigative Toxicology where it is thoughtfully applied to generate hypotheses about the mechanism of toxicity.


Mechanistic Assays and Screens

Project specific, issue-dependent assays developed as required

Custom Assay Development.  CXR has expertise in developing mechanistic in vitro assays, for example mitochondrial toxicity assays. Other examples include:

  • The AREc32 cell line, an in vitro screen for electrophilic and antioxidant properties of chemicals
  • CYP19 and CYP51 inhibition assays, to assess if your compound is a potential endocrine disruptor
  • Tubulin polymerisation and depolymerisation
  • Competition radioligand binding on rat cerebral membranes